Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has obtained a $225 million term loan facility from funds managed by SLR Capital Partners (“SLR”). This...

Click to view original post